Allergan Botox Settlement and Corporate Integrity Agreement
This week, the United States Department of Justice (DOJ) announced that it has reached a resolution regarding the previously…
Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Tag
FDA
Milwaukee Journal Sentinel: The Case of BMP-2 Ignoring Any Benefit from…
Progress in medicine is essential for discovering new ways to make people healthier, experience less pain, and to live longer. The…
FDA and Disease Awareness Programs
Non product specific, non accredited education programs focusing on disease state awareness are one of the most recent additions…
FDA Opioid REMS: ACPE Outlines Pharmacists Role in Education
During last month’s Joint Meeting of the Anesthetic and Life Drugs Advisory Committee (ALSDAC) & Drug Safety and Risk…
FDA: Warning Letters May Double in 2010
A recent article in MM&M highlighted how warning letters (found here) sent by the Food and Drug Administration’s (FDA)…
FDA Opioid REMS Advisory Panel Focus on CME for Improving Practice
As we noted last week, Murray Kopelow, M.D., M.S., Chief Executive and Secretary for the Accreditation Council for Continuing…
FDA Pain REMS Advisory Committee to Include Presentations on Continuing…
Today, Murray Kopelow, M.D., M.S., Chief Executive and Secretary for the Accreditation Council for Continuing Medical Education…
FDA Avandia Hearing Update – Committee Votes to Keep Avandia on the Market…
The FDA advisory panel on Avandia voted in favor of keeping Avandia (rosiglitizone) on the market the vote breaks down as…
FDA Direct to Consumer Proposed Rule: Advertising Coalition’s Response
The Advertising Coalition recently sent comments to the Food and Drug Administration (FDA) in response to a Notice of Proposed…
FDA Turns to CME for Risk Evaluation and Mitigation Strategy (REMS) Pain…
According to a FDA memo and recent article in the RPM Report, “continuing medical education (CME) has been under attack in…